课题基金 / 基金详情

Frontiers: University of Kansas Clinical and Translational Science Institute

Frontiers: University of Kansas Clinical and Translational Science Institute
前沿:堪萨斯大学临床与转化科学研究所
批准号:
9514338
负责人:
Richard J. Barohn
金额:
$406.37万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-07 至 2022-06-30

项目摘要

项目成果

Richard J. Barohn的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Contact PD/PI: Barohn, Richard Joel OVERALL: ABSTRACT Frontiers: The Heartland Institute for Clinical and Translational Research has been a catalyst for bringing together translational science investigators and stakeholders across the KC region, and beyond. Located at the University of Kansas Medical Center (KUMC) under the leadership of Dr. Barohn, our commitment to team science and multidisciplinary collaboration reaches beyond the walls of our academic health science center and promotes collaboration among investigators from diverse disciplines across local partner academic institutions and affiliated health care institutions. The vision of Frontiers is to contribute to and lead national efforts to transform the way we do clinical and translational research (CTR), and to ensure research is more rapidly and more efficiently translated to the point of care so that it may contribute to improved health. Specifically, Frontiers aims to: 1) Engage in bi-directional collaboration with all stakeholders to develop, demonstrate, and disseminate advances across the translational science spectrum that insures inclusion and integration of complex and diverse populations and individuals across the lifespan from birth to end of life; 2) Create a sustainable translational workforce of multi-disciplinary investigators, research personnel, and community and patient stakeholders in the use of translational science tools through innovative and creative programs; and 3) Strengthen institutional and regional infrastructure to accelerate translational research. We will accomplish these aims by drawing on our considerable strengths: a) developing informatics tools for making EHR data `research ready' and implementing clinic- and community-based registries for study recruitment and other translational research applications; b) nurturing and sustaining strong patient and community engagement relationships that will support research with African American, Latino, American Indian, LGBTQ, pediatric, geriatric, rare disease, prison, and rural populations; c) offering innovative training programs for the entire CTR workforce (not just investigators), including plans for comprehensive entrepreneurship and implementation research training and creating new team science brainstorming mechanisms that will lead to multidisciplinary discovery projects and d) advancing medical devices and re-purposed drugs to patients through novel strategies developed by Frontiers' Institute for Advancing Medical Innovations (IAMI)that is nationally known for its product development translational research and high impact collaborations with industry, academia, government, and disease philanthropy partners. All Frontiers units are linked by a group of Navigators that can be accessed by Frontiers investigative teams and community partners. These plans position Frontiers to contribute to goals, and lead initiatives of the CTSA network by building on technological, computational, and health/disease knowledge to advance translational research. Project Summary/Abstract Page 274 Contact PD/PI: Barohn, Richard Joel OVERALL NARRATIVE Frontiers: The Heartland Institute for Clinical and Translational Research provides infrastructure and educational programs to develop the next generation of CTR investigative teams. As a regional organization involving two states and three universities, Frontiers is able to blend the best resources available to advance team, community and clinical translational science. This results in accelerating discoveries and research findings that may be more rapidly brought to the point of care and contribute to population health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Frontiers: University of Kansas Clinical and Translational Science Institute
Models of Neuromuscular Disease Across the Lifespan
A Phase II Trial of Rituximab In Myasthenia Gravis
  • 批准号:
    8644497
  • 项目类别:
  • 资助金额:
    $130.54万
  • 财政年份:
    2013
  • 负责人:
    Richard J. Barohn
  • 依托单位:
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
海外基金